Hepatitis B: History and Discovery

Hepatitis B is a viral infection of the liver, spread chiefly through blood and from mother to child at birth. Its modern story begins not with a virus under a microscope but with a mysterious protein in a blood sample. In 1965, Baruch Blumberg identified the “Australia antigen” in the serum of an Australian Aboriginal person; within three years it was recognized as the surface coat of the hepatitis B virus, and by 1970 David Dane had photographed the whole virus particle. That chain of discovery made it possible to screen the blood supply, and then to build a vaccine — the first vaccine ever shown to prevent a major human cancer, because long-term hepatitis B is a leading cause of liver cancer. This page traces that history honestly, from a puzzling antigen to a Nobel Prize, a vaccine, and today’s powerful antiviral medicines.

Table of Contents

  1. An Ancient Disease, A Modern Name
  2. The Australia Antigen (1965)
  3. Linking the Antigen to Hepatitis B (1967–1968)
  4. The Dane Particle: Seeing the Whole Virus (1970)
  5. Safer Blood: Screening the Transfusion Supply
  6. The First Anti-Cancer Vaccine (1981 and 1986)
  7. The Nobel Prize and a Scientific Legacy (1976)
  8. Modern Antivirals and the Global Picture
  9. Legacy: What the Discovery Changed
  10. Research Papers and References
  11. Connections

An Ancient Disease, A Modern Name

Epidemics of jaundice — the yellowing of skin and eyes that signals a struggling liver — were recorded in antiquity, and physicians long suspected that some forms of jaundice spread from person to person. For most of medical history, however, “hepatitis” was simply a description of an inflamed liver, with no understanding of cause. A turning point came in the 1880s, when an outbreak of jaundice among shipyard and factory workers in Bremen, Germany, followed a smallpox vaccination campaign that used human lymph; the physician A. Lurman traced the cases to the inoculation, an early hint that something in human blood could transmit liver disease.

During the twentieth century, doctors gradually distinguished two broad patterns. “Infectious hepatitis,” which spread by the fecal–oral route and had a short incubation, would later be named hepatitis A. “Serum hepatitis,” which followed transfusions, injections, and contaminated needles after a long, silent incubation, would later be named hepatitis B. Human transmission experiments in the 1940s confirmed that serum hepatitis traveled in blood, but the agent itself remained invisible — too small to see and impossible to grow in the laboratory. By the early 1960s, serum hepatitis was a known and feared hazard of blood transfusion with no test to detect it.

The breakthrough, when it came, arrived from an unexpected direction. It was not produced by a virologist hunting for a hepatitis germ, but by a physician-scientist studying inherited differences in human blood proteins across populations — a reminder that major discoveries often emerge sideways, from a question nobody thought to connect to the answer.

Back to Table of Contents

The Australia Antigen (1965)

Baruch S. Blumberg (1925–2011) was an American physician and biochemist whose research focused on inherited variation in blood — why blood proteins differ from one population to another, and how those differences relate to disease susceptibility. To find such variants, he and his collaborator Harvey Alter tested the blood of patients who had received many transfusions, reasoning that their immune systems might have made antibodies against proteins they themselves lacked. In 1965, one such antibody reacted with a protein found in a blood sample from an Australian Aboriginal person. Because of its geographic origin, Blumberg named the unknown protein the “Australia antigen.”

At first the meaning of the Australia antigen was unclear. Blumberg’s 1967 paper described it appearing in a curious mix of people — in some patients with leukemia, in children with Down syndrome living in institutions, and, tellingly, in patients with hepatitis. The pattern was puzzling until the institutional clue was followed up: people in crowded residential settings, and patients exposed to many transfusions, were exactly the groups at high risk of catching serum hepatitis. A pivotal observation reportedly came when a young laboratory technician in Blumberg’s group, initially Australia-antigen negative, later tested positive and then developed hepatitis — a real-time link between the marker and the disease.

This is the foundational fact of the modern hepatitis B story, and it is well documented: a single mysterious blood antigen, named for the donor’s origin and stumbled upon during population-genetics research, turned out to be a fingerprint of one of the world’s most important infectious diseases. The discovery is firmly attributed to Blumberg and colleagues in 1965, with the antigen formally reported in 1967.

Back to Table of Contents

Linking the Antigen to Hepatitis B (1967–1968)

Between 1967 and 1968, several research groups converged on the same conclusion: the Australia antigen was specifically tied to serum hepatitis. The New York virologist Alfred M. Prince showed in 1968 that the antigen (which he called the “SH antigen,” for serum hepatitis) appeared in patients incubating long-incubation serum hepatitis but not short-incubation infectious hepatitis — cleanly separating what we now call hepatitis B from hepatitis A. Working independently in Japan, Kazuo Okochi confirmed the association and carried out early transfusion studies showing that blood carrying the antigen was far more likely to transmit hepatitis to the recipient.

As the evidence accumulated, the protein was recognized as part of the outer envelope of the hepatitis B virus, and the name was standardized to the hepatitis B surface antigen (HBsAg) — the term still used in every clinic and blood bank today. A positive HBsAg result means a person is currently infected with hepatitis B and is potentially infectious to others. What had been a curiosity of blood-group research in 1965 had become, within three years, a defined and detectable marker of a major virus.

It is worth being precise about credit here, because the history is genuinely shared. Blumberg discovered and named the antigen; Prince and Okochi, among others, established its specific link to serum hepatitis. Multiple investigators contributed to recognizing that the antigen marked the hepatitis B virus, and the historical literature reflects that collaborative, sometimes competitive, reality.

Back to Table of Contents

The Dane Particle: Seeing the Whole Virus (1970)

Detecting HBsAg told scientists the virus was present, but no one had yet seen the complete infectious particle. The blood of an infected person contains an enormous excess of empty subviral shells — small spheres and filaments made only of surface antigen — that outnumber the actual virus by a thousand to a hundred thousand to one. Early electron-microscope images therefore captured mostly these decoy particles, not the virus itself.

In 1970, the British pathologist David S. Dane, working with colleagues at the Middlesex Hospital in London, used electron microscopy to examine plasma from blood donors implicated in post-transfusion hepatitis and identified a larger, double-shelled particle about 42 nanometres across — an outer envelope of HBsAg surrounding an inner core that contained the viral DNA. This was the complete, intact hepatitis B virion. The particle became known as the “Dane particle,” a name introduced shortly afterward by the virologist June Almeida in 1971 and still used today.

Seeing the whole virus mattered enormously. It confirmed that the Australia antigen was indeed the coat of a real virus, revealed the virus’s distinctive structure (a surface shell, a core antigen, and a small partly double-stranded DNA genome), and gave researchers concrete targets for diagnostic tests and, eventually, vaccines. By 1970, hepatitis B had been transformed from an invisible “serum hepatitis” agent into a virus with a known appearance, a known marker, and a known mode of spread.

Back to Table of Contents

Safer Blood: Screening the Transfusion Supply

The most immediate human benefit of the discovery had nothing to do with treating the sick — it was preventing new infections in the blood supply. Before HBsAg testing, transfusions were a major route of hepatitis B transmission, and post-transfusion hepatitis was a common, sometimes fatal, complication of surgery and trauma care. The new antigen test changed that almost overnight: blood banks could now screen donated units, discard those carrying HBsAg, and dramatically cut the risk of giving the virus to a patient.

Routine donor screening for the Australia antigen / HBsAg spread through the United States and other countries in the early 1970s. Studies of the era documented sharp drops in transfusion-associated hepatitis B once screening became standard. This was a vivid demonstration of how a basic-science finding — an unexplained antigen in one blood sample — can translate, within a few years, into a concrete public-health intervention that protects millions of patients.

Screening also exposed how widespread silent infection was. Because many HBsAg carriers feel perfectly well, testing donors revealed a large reservoir of chronic, asymptomatic hepatitis B in the general population — knowledge that would shape the case for universal vaccination in the decades to follow.

Back to Table of Contents

The First Anti-Cancer Vaccine (1981 and 1986)

Blumberg made a second crucial leap. He reasoned that the abundant empty surface-antigen particles circulating in carriers’ blood — the harmless decoy shells, free of viral DNA — could themselves be purified and used to provoke protective immunity, in effect a ready-made vaccine antigen. Working with the microbiologist Irving Millman at the Fox Chase Cancer Center, Blumberg developed a method to isolate and inactivate HBsAg from human plasma. In October 1969 the two filed a patent application covering the vaccine concept and production process, which was granted in the early 1970s.

Turning that concept into a licensed product fell to the legendary vaccinologist Maurice Hilleman and his team at Merck. They produced the first hepatitis B vaccine, Heptavax-B, from the plasma of people chronically infected with the virus, purifying the surface-antigen particles and treating them with a sequence of chemical steps (including pepsin, urea, and formaldehyde) to destroy any residual infectious material. This plasma-derived vaccine was licensed in the United States in 1981 and proved both safe and effective. Hilleman regarded it as one of his greatest achievements.

A plasma-derived vaccine had obvious limits — it depended on human blood from infected donors. The solution was genetic engineering. Scientists inserted the gene for HBsAg into yeast, which then manufactured the surface antigen in fermentation tanks with no human blood involved. Merck’s recombinant vaccine, Recombivax-HB, came to market in 1986; it was among the first vaccines made by recombinant DNA technology, and the plasma-derived product was phased out. Crucially, because chronic hepatitis B is a leading cause of liver cancer (hepatocellular carcinoma), preventing the infection prevents the cancer — which is why the hepatitis B vaccine is widely described as the first vaccine to protect against a major human cancer, an “anti-cancer” vaccine. Real-world programs, beginning with Taiwan’s universal infant vaccination in 1984, have since shown measurable falls in childhood liver cancer.

Back to Table of Contents

The Nobel Prize and a Scientific Legacy (1976)

In 1976, Baruch Blumberg was awarded the Nobel Prize in Physiology or Medicine — an honor he shared that year with D. Carleton Gajdusek — cited for discoveries concerning “new mechanisms for the origin and dissemination of infectious diseases.” Blumberg’s share recognized the chain of work that began with the Australia antigen: identifying the marker of hepatitis B, enabling blood-bank screening, and laying the groundwork for the vaccine. It is one of the relatively rare instances in which a single line of discovery led, within roughly a decade, to a diagnostic test, a public-health measure, and a preventive vaccine — and was recognized at the highest level while its inventor was still actively building on it.

Blumberg’s career remained wide-ranging. He later served as director of the NASA Astrobiology Institute, applying his curiosity about the origins and spread of life to questions far beyond the liver. The Hepatitis B Foundation’s research institute now bears his name, and he is remembered both for a specific triumph and for a style of science — following an unexpected observation wherever it leads — that produced one of the great public-health success stories of the twentieth century.

Honesty about the collaborative nature of the work does not diminish Blumberg’s achievement; it sharpens it. He provided the original observation and the unifying insight, and he pursued both the diagnostic and the preventive payoff. Others — Alter, Prince, Okochi, Dane, Millman, Hilleman, and many more — supplied indispensable pieces. The result was a coordinated advance no single person could have completed alone.

Back to Table of Contents

Modern Antivirals and the Global Picture

Vaccination prevents new infections, but it cannot help the hundreds of millions of people already living with chronic hepatitis B. For them, the major advance has been antiviral medicine. After the limited early use of interferon, the field was transformed by oral nucleoside and nucleotide analogues that suppress viral replication. Today the preferred first-line agents are tenofovir (as tenofovir disoproxil fumarate or tenofovir alafenamide) and entecavir — potent, well-tolerated, once-daily pills with a high barrier to resistance. They do not usually cure the infection, but by driving the virus to undetectable levels they greatly reduce the risk of cirrhosis and liver cancer and can keep the liver healthy for decades.

The global burden remains immense. The World Health Organization estimated that in 2022 roughly 254 million people were living with chronic hepatitis B, with about 1.1 million deaths that year, mostly from cirrhosis and liver cancer. The disease is most common in the Western Pacific and African regions. A particular tragedy is that diagnosis and treatment rates are very low — only a small fraction of those infected have been identified, and fewer still are on therapy — even though effective, increasingly affordable antivirals exist. WHO has set a goal of eliminating viral hepatitis as a public-health threat by 2030.

Two prevention measures from this history matter most for the global fight. The first is the birth-dose vaccine: giving hepatitis B vaccine within 24 hours of birth, because mother-to-child transmission at delivery is the dominant route in high-burden regions and is especially likely to cause lifelong chronic infection. The second is continued blood and injection safety, the modern descendant of the donor-screening revolution of the 1970s. Together with antivirals for those already infected, these tools make hepatitis B one of the most preventable of the world’s great infectious diseases.

Back to Table of Contents

Legacy: What the Discovery Changed

In the span of a single human generation, hepatitis B went from an invisible, untreatable, unpreventable hazard to a virus that can be detected with a simple blood test, blocked with a vaccine given on the first day of life, and controlled with a daily pill. Few stories in medicine show so clearly how curiosity-driven research — in this case, a study of inherited blood proteins that was never aimed at hepatitis at all — can cascade into diagnostics, public-health programs, and a vaccine that prevents cancer.

The discovery also reshaped how scientists think about the links between chronic infection and cancer. Establishing that a virus could cause a common human cancer, and that vaccinating against the virus could prevent that cancer, helped open the broader field of cancer prevention through infection control — a path later followed by the human papillomavirus (HPV) vaccine against cervical cancer. Hepatitis B was the proof of concept.

For the reader, the practical takeaways from this history are simple and hopeful: hepatitis B is preventable by a safe, long-proven vaccine; it spreads mainly through blood and from mother to child, not through casual contact; testing identifies silent carriers who can then be protected and monitored; and for those already infected, modern antivirals can keep the liver healthy for a lifetime. Understanding where this knowledge came from makes its everyday use — a newborn’s first injection, a screened bag of donor blood — all the more remarkable.

Back to Table of Contents

Research Papers and References

The references below combine landmark historical papers (with real DOIs or PMIDs where confidently identified) and curated PubMed topic-search links into the discovery, vaccine, and treatment literature. Where a precise citation could not be verified with confidence, a PubMed topic search is provided instead. Each link opens in a new tab.

  1. Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA. 1965;191:541-546. — doi:10.1001/jama.1965.03080070025007
  2. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down’s syndrome, leukemia, and hepatitis. Annals of Internal Medicine. 1967;66(5):924-931. — doi:10.7326/0003-4819-66-5-924
  3. Blumberg BS. Australia antigen and the biology of hepatitis B (Nobel Lecture). Science. 1977;197(4298):17-25. — doi:10.1126/science.325649
  4. Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. PNAS. 1968;60(3):814-821. — doi:10.1073/pnas.60.3.814
  5. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. The Lancet. 1970;1(7649):695-698. — doi:10.1016/S0140-6736(70)90926-8
  6. Okochi K, Murakami S. Australia antigen, transfusion, and hepatitis. Vox Sanguinis. 1968 (and 1970 follow-up). — PubMed: Okochi, Australia antigen and transfusion
  7. Gerin JL, et al. / Hilleman MR, et al. Plasma-derived hepatitis B vaccine (Heptavax-B) development and licensure (1981). — PubMed: Hilleman plasma-derived hepatitis B vaccine
  8. Recombinant (yeast-derived) hepatitis B vaccine — Recombivax-HB and the first recombinant DNA vaccine (1986). — PubMed: recombinant hepatitis B vaccine (yeast)
  9. Chang MH, et al. Universal hepatitis B vaccination and the decline of childhood hepatocellular carcinoma (Taiwan birth-dose program). New England Journal of Medicine. 1997;336:1855-1859. — doi:10.1056/NEJM199706263362602
  10. Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virology Journal. 2013;10:239. — doi:10.1186/1743-422X-10-239
  11. Blumberg BS, Millman I. Hepatitis B vaccine: the patent and the plasma-derived concept (Fox Chase). — PubMed: Blumberg and Millman hepatitis B vaccine
  12. Tenofovir and entecavir as first-line antiviral therapy for chronic hepatitis B (guideline evidence). — PubMed: tenofovir and entecavir for chronic hepatitis B
  13. Global burden of chronic hepatitis B and progress toward 2030 elimination. — PubMed: global burden of hepatitis B and elimination
  14. History of hepatitis B virus discovery and the Australia antigen. — PubMed: history of hepatitis B virus discovery

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents